|0.8350||-0.0019||-0.23%||Vol 115.15K||1Y Perf -66.79%|
|Aug 11th, 2022 15:59 DELAYED|
|- -||0.00 0.19%|
|Target Price||8.50||Analyst Rating||Strong Buy 1.00|
|Potential %||917.96||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||5.11||Earnings Rating||Strong Buy|
|Market Cap||77.06M||Earnings Date||2nd Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.13|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||348.99K|
|Avg. Monthly Volume||185.08K|
|Avg. Quarterly Volume||246.18K|
Aptose Biosciences Inc. (NASDAQ: APTO) stock closed at 0.835 per share at the end of the most recent trading day (a -0.23% change compared to the prior day closing price) with a volume of 115.15K shares and market capitalization of 77.06M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 31 people. Aptose Biosciences Inc. CEO is William G. Rice.
The one-year performance of Aptose Biosciences Inc. stock is -66.79%, while year-to-date (YTD) performance is -38.15%. APTO stock has a five-year performance of -42.41%. Its 52-week range is between 0.7118 and 3.125, which gives APTO stock a 52-week price range ratio of 5.11%
Aptose Biosciences Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 1.17, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -66.83%, a ROC of -68.91% and a ROE of -71.90%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aptose Biosciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Aptose Biosciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aptose Biosciences Inc. is Strong Buy (1), with a target price of $8.5, which is +917.96% compared to the current price. The earnings rating for Aptose Biosciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aptose Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aptose Biosciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 14.52, ATR14 : 0.06, CCI20 : 63.83, Chaikin Money Flow : -0.17, MACD : 0.00, Money Flow Index : 46.54, ROC : 7.43, RSI : 40.46, STOCH (14,3) : 60.09, STOCH RSI : 0.89, UO : 54.48, Williams %R : -39.91), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aptose Biosciences Inc. in the last 12-months were: Denis R. Burger (Buy at a value of $14 490), Denis R. Burger (Option Excercise at a value of $11 051), Erich M. Platzer (Buy at a value of $454 240), William G. Rice (Buy at a value of $69 645)
Thu, 24 Mar 2022 10:40 GMT Aptose Biosciences (APTO) Gets a Buy Rating from RBC Capital- TipRanks. All rights reserved.
Wed, 23 Mar 2022 20:35 GMT Aptose Biosciences (APTO) Gets a Buy Rating from Alliance Global Partners- TipRanks. All rights reserved.
Wed, 23 Mar 2022 12:25 GMT Analysts Top Healthcare Picks: Aptose Biosciences (APTO), Frequency Therapeutics (FREQ)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.